Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 29 entities : Abbvie inc. save search
Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Published: 2021-06-29 (Crawled : 20:00) - biospace.com/
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
|
| O: -0.31%
H: 0.09%
C: -0.31%
phase 3 ulcerative colitis
AbbVie’s Rinvoq Shows Promise as Maintenance Drug for Ulcerative Colitis
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
|
| O: -0.31%
H: 0.09%
C: -0.31%
drug ulcerative colitis
Age-related Macular Degeneration Market in Pharmaceutical Industry | Technavio
Published: 2021-06-29 (Crawled : 03:00) - prnewswire.com
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
|
| O: -0.31%
H: 0.09%
C: -0.31%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
macular market
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
ILAG | $0.51 6.03% 29.06% 430K
|
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.